Overview

Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)

Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The main objective of this study is to demonstrate the efficacy and safety of an investigational intravenous (IV) iron, ferric carboxymaltose (FCM), compared to oral iron in subjects who have iron deficiency anemia (IDA) and have shown an unsatisfactory response to oral iron.
Phase:
Phase 3
Details
Lead Sponsor:
American Regent, Inc.
Luitpold Pharmaceuticals
Treatments:
Ferric Compounds
Iron